JPH05201862A - 増殖性疾患の治療のためのジピリダモル - Google Patents

増殖性疾患の治療のためのジピリダモル

Info

Publication number
JPH05201862A
JPH05201862A JP4308615A JP30861592A JPH05201862A JP H05201862 A JPH05201862 A JP H05201862A JP 4308615 A JP4308615 A JP 4308615A JP 30861592 A JP30861592 A JP 30861592A JP H05201862 A JPH05201862 A JP H05201862A
Authority
JP
Japan
Prior art keywords
dipyridamole
formulation
site
growth
local delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP4308615A
Other languages
English (en)
Japanese (ja)
Inventor
Raymond F Kauffman
レイモンド・フランシス・カウフマン
Jai Pal Singh
ジャイ・パル・シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH05201862A publication Critical patent/JPH05201862A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP4308615A 1991-11-21 1992-11-18 増殖性疾患の治療のためのジピリダモル Withdrawn JPH05201862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US795434 1991-11-21
US07/795,434 US5270047A (en) 1991-11-21 1991-11-21 Local delivery of dipyridamole for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
JPH05201862A true JPH05201862A (ja) 1993-08-10

Family

ID=25165502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4308615A Withdrawn JPH05201862A (ja) 1991-11-21 1992-11-18 増殖性疾患の治療のためのジピリダモル

Country Status (12)

Country Link
US (2) US5270047A (cg-RX-API-DMAC10.html)
EP (1) EP0543653A1 (cg-RX-API-DMAC10.html)
JP (1) JPH05201862A (cg-RX-API-DMAC10.html)
KR (1) KR930009607A (cg-RX-API-DMAC10.html)
AU (1) AU661067B2 (cg-RX-API-DMAC10.html)
CA (1) CA2083223A1 (cg-RX-API-DMAC10.html)
HU (1) HU212422B (cg-RX-API-DMAC10.html)
MX (1) MX9206610A (cg-RX-API-DMAC10.html)
NO (1) NO924461L (cg-RX-API-DMAC10.html)
RU (1) RU2084224C1 (cg-RX-API-DMAC10.html)
TW (1) TW252917B (cg-RX-API-DMAC10.html)
ZA (1) ZA928832B (cg-RX-API-DMAC10.html)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
JPH08506112A (ja) * 1993-01-28 1996-07-02 ネオルックス コーポレイション 血管平滑筋細胞の治療用インヒビター
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
EP1652539B8 (en) * 1993-07-19 2011-06-15 Angiotech Pharmaceuticals, Inc. Method of manufacturing a stent comprising an anti-angiogenic composition
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5521191A (en) * 1994-10-17 1996-05-28 Washington University Method for treatment of arterial stenosis
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US7550005B2 (en) 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5951586A (en) * 1996-05-15 1999-09-14 Medtronic, Inc. Intraluminal stent
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EP1045676A1 (en) 1997-08-26 2000-10-25 Technion Research & Development Foundation Ltd. Intravascular apparatus and method
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
RU2157199C2 (ru) * 1998-04-03 2000-10-10 Вахрушев Яков Максимович Способ лечения хронического панкреатита
EP1174157B1 (en) 1998-04-27 2005-06-29 Surmodics Inc. Bioactive agent release coating
WO2000010622A1 (en) 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US6168619B1 (en) * 1998-10-16 2001-01-02 Quanam Medical Corporation Intravascular stent having a coaxial polymer member and end sleeves
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6730313B2 (en) 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
DE20122506U1 (de) 2000-10-16 2005-12-08 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10119680A1 (de) * 2001-04-20 2002-11-14 Boehringer Ingelheim Pharma Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
HRP20040388A2 (en) 2001-10-05 2004-10-31 Combinatorx Combinations for the treatment of immunoinflammatory disorders
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
US20030083614A1 (en) * 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
JP5105697B2 (ja) * 2002-01-18 2012-12-26 シヴィダ・インコーポレイテッド コドラッグのコントロールデリバリ用ポリマー性ゲルシステム
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
AU2003205315A1 (en) * 2002-01-22 2003-09-02 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DE60335801D1 (de) * 2002-07-12 2011-03-03 Cook William Europ Beschichtete medizinische vorrichtung
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US20040162542A1 (en) * 2002-12-03 2004-08-19 Endobionics, Inc. Methods and systems for treating the vasculature with estrogens
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007532187A (ja) 2004-04-06 2007-11-15 サーモディクス，インコーポレイティド 生物活性物質のためのコーティング組成物
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
WO2009038708A1 (en) * 2007-09-19 2009-03-26 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
EP2231129A4 (en) * 2007-12-17 2013-01-30 Zalicus Inc THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP4295906A3 (en) 2016-09-22 2024-02-21 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
AU2018272061A1 (en) 2017-05-26 2020-01-02 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
CN212631328U (zh) 2018-03-14 2021-03-02 墨卡托医疗系统公司 用于局部药物递送的医疗器械
WO2021077070A1 (en) * 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
CN118903419A (zh) * 2020-02-10 2024-11-08 广州市妇女儿童医疗中心 Pde抑制剂或其盐在制备用于预防和/或治疗胃肠道疾病的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1208516A (en) * 1982-04-02 1986-07-29 Harvey Wolinsky Methods and apparatus for relieving arterial constrictions
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
ATE121954T1 (de) * 1988-08-24 1995-05-15 Marvin J Slepian Endoluminale dichtung mit bisdegradierbaren polymeren.
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
ES2078936T3 (es) * 1989-01-31 1996-01-01 Bard Inc C R Cateter y metodo para aplicar localmente la medicacion a la pared de un vaso sanguineo o de otro lumen corporal.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors

Also Published As

Publication number Publication date
CA2083223A1 (en) 1993-05-22
AU661067B2 (en) 1995-07-13
RU2084224C1 (ru) 1997-07-20
EP0543653A1 (en) 1993-05-26
AU2845492A (en) 1993-05-27
NO924461D0 (no) 1992-11-19
KR930009607A (ko) 1993-06-21
HU212422B (en) 1996-06-28
US5270047A (en) 1993-12-14
US5314688A (en) 1994-05-24
NO924461L (no) 1993-05-24
ZA928832B (en) 1994-05-16
MX9206610A (es) 1993-05-01
TW252917B (cg-RX-API-DMAC10.html) 1995-08-01
HUT70034A (en) 1995-09-28
HU9203626D0 (en) 1993-01-28

Similar Documents

Publication Publication Date Title
US5314688A (en) Local delivery of dipyridamole for the treatment of proliferative diseases
US5599844A (en) Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Douglas et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670.
US6429232B1 (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
Edelman et al. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.
US6544541B1 (en) Devices and compounds for treating arterial restenosis
Fishbein et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis
Mayberg et al. Radiation inhibition of intimal hyperplasia after arterial injury
RU2322984C2 (ru) Комбинации для лечения иммуновоспалительных расстройств
WO1995003795A9 (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
CA2202630A1 (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
US20080085293A1 (en) Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
Matsumura et al. Intravesical chemotherapy with 4′-epi-Adriamycin in patients with superficial bladder tumors
DE69921980T2 (de) Periadventitiales verabreichungssystem
KR20010052305A (ko) 약제 조성물
Sharpe et al. Anesthetic considerations for the previously transplanted patient
Coats et al. Inhibition of non-Ras protein farnesylation reduces in-stent restenosis
Pazdur et al. Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model
JP2002536406A (ja) 細胞増殖の治療用アルキル化剤
KR100987557B1 (ko) 혈관 재협착 치료 또는 예방용 조성물
US6498152B1 (en) Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis
Jung et al. Perivascular delivery of rapamycin in pluronic gel inhibits neointimal hyperplasia in a rat carotid artery injury model, and the complementary role of carotid arteriography
Low et al. Role of cimetidine in the prevention of intimal hyperplasia in rat carotid artery
RU1821211C (ru) Гиполипидемическое средство
DE102007016283A1 (de) Verwendung von 2-Deoxy-D-Glucose zur Verhinderung oder Behandlung von Arteriosklerose und Arteriothrombose

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20000201